Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15701978 | 0.81 | KMT2A (0.63) | KMT2AHPGDMEN1ALDH1A1TDP1 | |
| SCHEMBL6361997 | 0.77 | MEN1 (0.55) | KMT2AHPGDMEN1ALDH1A1TDP1 | |
| SCHEMBL22317081 | 0.77 | KMT2A (0.40) | KMT2AHPGDMEN1ALDH1A1TDP1 | |
| SCHEMBL11225239 | 0.77 | KMT2A (0.40) | KMT2AHPGDMEN1ALDH1A1MAPT | |
| SCHEMBL18919835 | 0.76 | KMT2A (0.39) | KMT2AHPGDMEN1ALDH1A1TDP1 | |
| SCHEMBL13337842 | 0.74 | KMT2A (0.51) | KMT2AHPGDMEN1ALDH1A1 | |
| SCHEMBL10488519 | 0.73 | TP53 (0.53) | HPGDALDH1A1TDP1MAPTTP53 | |
| SCHEMBL15702008 | 0.71 | TPMT (0.42) | HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL10013772 | 0.71 | POLB (0.64) | KMT2AMEN1TDP1 | |
| SCHEMBL31135393 | 0.71 | MEN1 (0.41) | KMT2AMEN1ALDH1A1TDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278959-B2 | Processes and reagents for making diaryliodonium salts | NUTECH VENTURES (US) | 2016-03-08 | — | — | US | disclosed |
| US-20140121371-A1 | PROCESSES AND REAGENTS FOR MAKING DIARYLIODONIUM SALTS | Ground Fluor Pharmaceuticals, Inc. (US) | 2014-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121371-A1 | PROCESSES AND REAGENTS FOR MAKING DIARYLIODONIUM SALTS | ABL1, ARSA, AADAC | KMT2A 2400/4885HPGD 3858/4885MEN1 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.